Meridian Bioscience has obtained the US. Food and Drug Administration (FDA) approval for its lateral flow device, TRU Legionella, to detect legionellosis.
TRU Legionella provides optimized detection of Legionella pneumophila serogroup 1, which is most commonly associated with Legionnaire’s disease.
Meridian Bioscience CEO John Kraeutler said TRU Legionella provides labs with a highly accurate tool that can speed the detection of an under-diagnosed pathogen enabling rapid treatment for the patient.
"TRU Legionella is in distribution, via Meridian Bioscience Europe, for our European customers," Kraeutler added.